# A Study of Anlotinib in Patients With Hepatocellular Carcinoma

> **NCT02809534** · PHASE2 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Anlotinib

## Key facts

- **NCT ID:** NCT02809534
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-09
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2016-09-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02809534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02809534, "A Study of Anlotinib in Patients With Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02809534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*